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study was to estimate the cost-effectiveness of ivabradine versus diltiazem as an alter-
native bradycardic agent in these patients. METHODS: A Markov chain Monte Carlo 
simulation model was used to estimate the effect of HR lowering on cardiovascular 
outcomes, including the economic consequences of ivabradine, 7.5 mg twice daily 
versus diltiazem, 240 mg once a day. Included patients had resting HR  70 bpm.  
Outcome events considered were acute myocardial infarction, stroke, heart failure and 
death, as well as revascularization procedures (coronary artery bypass graft and per-
cutaneous coronary interventions). HR distribution was modelled as a gamma func-
tion and survival and time to hospitalization were modelled with weibull functions. 
Health outcomes were measured in life years (LY) and quality-adjusted life years 
(QALY). Time-horizon was set at 20 years and health outcomes and costs were dis-
counted at 1.5% and 4%, respectively. The analysis was conducted following the 
Dutch guidelines for pharmacoeconomic research. RESULTS: For each 100 patients 
assumed to use ivabradine or diltiazem, ivabradine was estimated to gain 44 LY 
(95%CI: [24;70]) and 36 QALY (95%CI: [22;52]) versus diltiazem. Annual incremen-
tal per patient cost of ivabradine versus diltiazem was estimated at a178 (95%CI: 
[138;207]). The incremental cost-effectiveness ratios for ivabradine versus diltiazem 
were estimated at a7990 per LY and a9897 per QALY gained. The probability of   
accepting ivabradine following the informal Dutch willingness-to-pay threshold of 
a20,000 per QALY was estimated at 99%. CONCLUSIONS: Ivabradine was found 
to be a cost-effective alternative for the treatment of SA in patients with resting HR 
 70 bpm with contraindication or intolerance for beta-blockers.    
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OBJECTIVES: The aim of this study was to assess the clinical and economic beneﬁts 
of the stroke units compared with conventional care. METHODS: A Markov model 
was developed. Four clinical conditions were deﬁned : ﬁrst ischaemic event, ﬁrst cere-
bral haemorrhage, recurrent ischaemic , recurrent haemorrhagic. Three lines of man-
agement were identiﬁed after hospitalisation: rehabilitation, home, and geriatric 
institutions. Three levels of incapacity were identiﬁed using the Barthel index. 
The clinical beneﬁt was measured as survival without loss of independence (Barthel 
95–100). The relative risks of death or institutionalisation, or death or dependence 
after passage through a stroke unit were analysed in comparison with conventional 
hospital services from the data available in the Cochrane meta-analyse on stroke 
units. All of the cost calculations were made from the perspective of the health care 
system. Expenditures were discounted at a rate of 5%. RESULTS: The mean cost per 
patient at 5 years was a30,983 in a conventional care unit and a34,638. in a stroke 
unit.After 5 years, the cumulative expenditure for the care of 120,000 patients 
in conventional care units was a3.710 million. Where care is generalised in a stroke 
unit, this ﬁgure increases to a4.160 million. In the 5 years following hospitalisation, 
patients cared for in stroke units survive for more trimesters without sequalae than 
those cared for conventionally (11.6 vs. 8.28). Comparison of the additional cost and 
added efﬁcacy gave a ratio of a1359 per year of life gained without disability (Barthel 
95–100). a513). CONCLUSIONS: The cost-effectiveness ratio between for stroke 
units is much lower than the threshold for cost-effectiveness considered acceptable by 
the international scientiﬁc community (a53,400). This extremely favourable ratio 
could justify organisational changes and the establishment of stroke units in the hos-
pital environment.
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OBJECTIVES: In Russian Federation (RF) just 25% of patients with hypertension 
(HT) reach target blood pressure goals. Moreover, patients with concomitant Type-2 
diabetes have a small chance of successful treatment. Direct Renin Inhibitors (DRI) 
—the newest class of antihypertensive drugs with clinically important nephroprotec-
tive properties. The aim of the study was to assess cost-effectiveness ratio of DRI 
aliskiren in treatment of patients with HT, Type-2 diabetes and nephropathy in Russia. 
METHODS: A lifetime Markov model basing on results of AVOID study was devel-
oped. Incremental cost-effectiveness ratio (ICER) of aliskiren  losartan vs placebo  
losartan was assessed. In the model it is conservatively assumed that no additional 
beneﬁt of aliskiren is extended to periods after 6 months according to 6-months 
AVOID trial. Direct medical costs were calculated basing on tariffs of Federal Obliga-
tory Medical Insurance Fund of the RF. Health outcomes were quality-adjusted life 
years (QALY) and life-years gained (LYG). Clinical and economic outcomes were 
discounted at 3.5%. RESULTS: Cost-effectiveness of aliskiren for 60-years old 
patients in HT, Type-2 diabetes and nephropathy is within the range of 280 thous. 
rubles/LYG (300 thousand rubles/QALY) for early overt nephropathy to 525 thou-
sand rubles/LYG (570 thousand rubles/QALY) for microalbuminuria. Sensitivity 
analysis depending on age of patients between 55–65 years old demonstrates non-sig-
niﬁcant difference (o 5%) of ICER. In accordance with the budjet of the RF in 2009, 
gross domestic product per capita is 360 thous. rubles and ICER is within the range 
of values that are considered acceptable for Russian Health Care system. CONCLU-
SIONS: ICER of aliskiren usage in antihypertensive treatment of patients with HT, 
Type 2 diabetes and nephropathy is comparable with ICER of other cardiovascular 
drugs included into Russian reimbursement. So aliskiren have to be available for 
countrywide health care systems regardless of age of patients.
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OBJECTIVES: Translate clinical beneﬁts of raising HDL-C into life years saved (LYS) 
using randomized placebo controlled clinical trial data of NIASPAN as monotherapy 
(NER), or in combination with statin (NER/S), in patients with inadequate HDL-C 
control. METHODS: Two analyses were undertaken: translation of clinical beneﬁts 
into survival beneﬁts using NER, and NER/S, in patients lacking optimal HDL-C 
control. Validated equations (HDL-C Mortality Equations), were used to translate 
HDL-C and LDL-C into reductions in mortality. NER effects are taken from placebo-
controlled trials. Comparative efﬁcacy of NER/S is taken from seven clinical trials 
with NER/S versus a statin only. The treatment arms were categorized by dose and 
the weighted average effects were calculated for change from baseline in HDL-C as 
and LDL-C. RESULTS: Applying the regression parameter estimates from the vali-
dated equation (i.e., 1.02 for LDL-C and 1.51 for HDL-C) to NER trial results, and 
after adjusting for the placebo effect, yields the estimated percent reductions in car-
diovascular events, 23.22%, 34.89% and 36.4% at 1000 mg/day, 1500 mg/day and 
2000 mg per day, respectively. Translating increases in HDL-C by adding NER/S after 
adjusting for the statin alone effect are 0.10 mmol/L, 0.2213 mmol/L and 0.2063 mmol/
L for 1,000 mg, 1,500 mg and 2,000 mg per day, yielding 27.16, 59.75, and 55.7 lives 
saved per 10,000 patients. The Prospective Studies Collaborative report a 0.33 mmol/
L increase in HDL-C is associated with about a third (33%) lower IHD mortality. 
Weighted average increases in HDL-C, with NER/S are 0.318 mmol/L. Applying 
change in HDL-C values using the HDL-C Mortality Equations with bootstrapping, 
the hazard ratios are reduced by 29% [95% CI: 0.34 – 0.23], 30% [95% CI: 
0.35 – 0.24] and 32% [95% CI: 0.38 – 0.26]. CONCLUSIONS: Nicotinic acid 
increases survival in patients with low HDL-C when used as NER or NER/S.
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OBJECTIVES: In patients with acute coronary syndromes (ACS) undergoing percuta-
neous coronary intervention (PCI), the TRITON-TIMI 38 trial demonstrated that 
treatment with prasugrel vs. clopidogrel was associated with signiﬁcantly reduced rates 
of atherothrombotic events, though with increased risk of bleeding. We evaluated the 
long-term cost-effectiveness of a 12-month treatment with prasugrel vs. clopidogrel in 
the trial population, excluding patients with prior transient ischemic attack or stroke, 
from the perspective of the German health care system. METHODS: A Markov model 
was developed based on risk equations for cardiovascular death, myocardial infarction 
(MI) or stroke, bleeding, and rehospitalisation, derived from TRITON-TIMI 38 data 
(N  13,608 patients). Hospital readmissions captured during the trial in all patients 
from 8 countries (N  6705) were assigned to German diagnosis related groups, and 
hospitalisation costs continued to accrue beyond 12 months to all surviving patients. 
Long term survival and quality adjusted survival were estimated for the life-time of each 
patient. RESULTS: At 12 months, a difference in drug costs between prasugrel and 
clopidogrel of 105 (branded clopidogrel) to a416 (generic clopidogrel) per patient 
was partially or totally offset by hospital cost savings (a129 per patient) due princi-
pally to reduced rates of revascularization. In the longer-term, prasugrel was associated 
with higher total costs (a42 to a353 per patient), life expectancy gains of 0.07 years, 
due primarily to the reduced rate of MI, and 0.05 additional QALYs, resulting in 
incremental costs per life year saved and per QALY gained of a606 to a5074 and a799 
to a6689, respectively. Probabilistic sensitivity analysis indicated that prasugrel has a 
q79 to 88% probability of being more cost-effective than clopidogrel at a willingness 
to pay of a30,000 per QALY. CONCLUSIONS: Prasugrel given for up to 1 year in 
ACS-PCI patients is likely to be considered a highly cost-effective treatment strategy.
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OBJECTIVES: Albuminuria has been proven to be associated with renal disease 
progression and cardiovascular (CV) events. Limited evidence exists on the cost- 
